April 10, 2009 (Boston, Massachusetts) — Smoking has become the latest factor shown to affect responsiveness to clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis), with a new post hoc analysis ...

Clopidogrel is one of the most important drugs utilized for secondary prevention of ischemic events in patients with ACS who undergo PCI. Therefore, numerous investigations have been conducted to ...

New data have added more concerns about using morphine and clopidogrel together in patients presenting with non-ST-segment elevation ACS (NSTEACS). Previous studies have shown that morphine can reduce ...

The antiplatelet drug clopidogrel helps prevent stent-associated thrombosis, but the antiplatelet effects are quite variable and the clinical consequences can be serious. New findings show that the ...

The effect of single as compared with dual antiplatelet treatment on bleeding and thromboembolic events after transcatheter aortic-valve implantation (TAVI) in patients who do not have an indication ...

Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. At 12 ...

Antiplatelet therapy with the ADP P2Y12 receptor antagonist clopidogrel is recommended by current clinical practice guidelines to prevent atherothrombotic events in patients with coronary artery ...

Please provide your email address to receive an email when new articles are posted on . Among patients with non-ST-segment elevation ACS undergoing coronary angiography who were pretreated with ...

In this issue, Suh and colleagues report on the risk of atherothrombotic events in people taking clopidogrel.1 Their main objective was to link clopidogrel efficacy to the activity of a specific CYP3A ...